Showing 91 - 100 of 61,992
We examine the issue of new goods and price indexes for the important and tractable case of generic and branded drugs. By treating generics as entirely distinct goods and "linking them in" to indexes with fixed weights, the standard price indexes fail to reflect the substantial welfare gains to...
Persistent link: https://www.econbiz.de/10012474690
I evaluate how the probability of substitution of a prescribed drug in a pharmacy depends on the pharmacists' profits and patients' out of pocket costs. I use Finnish population-wide data covering all prescriptions of three popular antidepressants. I find that one euro increase in the total...
Persistent link: https://www.econbiz.de/10011954334
Persistent link: https://www.econbiz.de/10011821726
Persistent link: https://www.econbiz.de/10011900045
Persistent link: https://www.econbiz.de/10011660160
Economic literature has extensively studied how prices for incumbent pharmaceutical drugs respond to generic competition after entry. However, less attention has been paid to pricing behavior in anticipation of brand-to-brand competition. We contribute to this gap in the literature by both...
Persistent link: https://www.econbiz.de/10012453327
Generic pharmaceuticals provide low-cost access to treatment. Despite their chemical equivalence to branded products …
Persistent link: https://www.econbiz.de/10012455020
Persistent link: https://www.econbiz.de/10011999624
Persistent link: https://www.econbiz.de/10014556581
Persistent link: https://www.econbiz.de/10014514650